Steven M. Paul, Director at Sage Therapeutics, Inc. (SAGE), sold 20,000 shares at $68.12 ($1.4M) on 2015-07-01, disclosed to the SEC on 2015-07-02.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $67.46 | 803 | $54K | 3.9% |
| 2 | $68.12 | 9,702 | $661K | 47.6% |
| 3 | $68.90 | 1,859 | $128K | 9.2% |
| 4 | $70.50 | 1,600 | $113K | 8.1% |
| 5 | $71.47 | 5,336 | $381K | 27.5% |
| 6 | $72.44 | 700 |
| $51K |
| 3.7% |
| Total | $69.40 avg | 20,000 | $1.4M | 100% |
| Filing → |
| KRTX | BUY | 2021-08-18 | $501K | — | Filing → |
| ALNY | SELL | 2020-12-22 | $2.1M | — | Filing → |
| KRTX | SELL | 2020-06-30 | $60.5M | — | Filing → |